{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:40:54Z","timestamp":1787949654685,"version":"build-2784847793"},"reference-count":16,"publisher":"IMR Press","issue":"1","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Amiodarone is a common antiarrhythmic drug that is utilised in clinical practice and is associated with pulmonary toxicity. The most common form of pulmonary complication is interstitial pneumonitis which is treated with discontinuation of amiodarone and initiation of corticosteroids. Amiodarone-induced pulmonary eosinophilia is a rare complication of amiodarone therapy, with blood and pulmonary eosinophilia the predominant features. During the COVID-19 era, the incidence of delay in treatment of pulmonary pathology is also delayed due to the effort of excluding COVID-19 infection. Here we report a case of a 64-year-old man who developed eosinophilic pneumonia after initiation of amiodarone therapy, and the investigations required to exclude other forms of pulmonary toxicity. We also reviewed the effect of COVID-19 testing in the management of patients presenting with respiratory distress.<\/jats:p>","DOI":"10.31083\/j.rcm.2021.01.267","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:44:00Z","timestamp":1617324240000},"source":"Crossref","is-referenced-by-count":3,"title":["Case report of amiodarone-associated allergic pneumonitis amidst the COVID-19 pandemic"],"prefix":"10.31083","volume":"22","author":[{"given":"Meor","family":"Azraai","sequence":"first","affiliation":[{"name":"Department of Cardiology, Epworth Healthcare, Melbourne, 3121 Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"McMahon","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Epworth Healthcare, Melbourne, 3121 Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Dick","sequence":"first","affiliation":[{"name":"Department of Cardiology, Epworth Healthcare, Melbourne, 3121 Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clinical Pharmacokinetics. 1984; 9: 136-156.","DOI":"10.2165\/00003088-198409020-00002"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Dusman RE, Stanton MS, Miles WM, Klein LS, Zipes DP, Fineberg NS, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation. 1990; 82: 51-59.","DOI":"10.1161\/01.CIR.82.1.51"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Camus P, Colby TV, Rosenow EC. Amiodarone pulmonary toxicity. Drug-Induced and Iatrogenic Respiratory Disease (pp. 244-263). 2010.","DOI":"10.1201\/b13277-22"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Canadian Respiratory Journal. 2009; 16: 43-48.","DOI":"10.1155\/2009\/282540"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Schwaiblmair M, Berghaus T, Haeckel T, Wagner T, von Scheidt W. Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Clinical Research in Cardiology. 2010; 99: 693-700.","DOI":"10.1007\/s00392-010-0181-3"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone. Drug Safety. 2010; 33: 539-558.","DOI":"10.2165\/11532320-000000000-00000"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Cottin V, Frognier R, Monnot H, Levy A, DeVuyst P, Cordier J. Chronic eosinophilic pneumonia after radiation therapy for breast cancer. European Respiratory Journal. 2004; 23: 9-13.","DOI":"10.1183\/09031936.03.00071303"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Larsen BT, Vaszar LT, Colby TV, Tazelaar HD. Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodarone-induced lung toxicity. American Journal of Surgical Pathology. 2012; 36: 509-516.","DOI":"10.1097\/PAS.0b013e318243fd9a"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"LeVee A, Trieu M, Bhattacharyya S, Sandhu G. Eosinophilic pneumonia: a rare manifestation of amiodarone toxicity diagnosed using traditional bronchoscopy. Respiratory Medicine Case Reports. 2019; 27: 100856.","DOI":"10.1016\/j.rmcr.2019.100856"},{"key":"ref10","unstructured":"Lavaud F, Cossart C, Tack V, Bonnaud G. Follow-up of blood and alveolar hyper-eosinophilia in pneumopathy induced by amiodarone. Therapie. 1990; 45: 49-51. (In French)"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Alqaid A, Baskaran G, Dougherty C. Amiodarone-induced lung injury with bilateral lung pneumonitis and peripheral eosinophilia. American Journal of Therapeutics. 2016; 23: e1121-e1123.","DOI":"10.1097\/MJT.0000000000000250"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Yousefzai R, Bhimaraj A. Misdiagnosis in the COVID-19 era: when zebras are everywhere, don\u2019t forget the horses. JACC: Case Reports. 2020; 2: 1614-1619.","DOI":"10.1016\/j.jaccas.2020.04.018"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Harahsheh AS, Dahdah N, Newburger JW, Portman MA, Piram M, Tulloh R, et al. Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. Journal of Pediatrics. 2020; 222: 261-262.","DOI":"10.1016\/j.jpeds.2020.04.052"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Gandhi TK, Singh H. Reducing the risk of diagnostic error in the COVID-19 era. Journal of Hospital Medicine. 2020; 15: 363-366.","DOI":"10.12788\/jhm.3461"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Mossa-Basha M, Medverd J, Linnau KF, Lynch JB, Wener MH, Kicska G, et al. Policies and guidelines for COVID-19 preparedness: experiences from the University of Washington. Radiology. 2020; 296: E26-E31.","DOI":"10.1148\/radiol.2019201326"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Grange ES, Neil EJ, Stoffel M, Singh AP, Tseng E, Resco-Summers K, et al. Responding to COVID-19: the UW Medicine Information Technology Services Experience. Applied Clinical Informatics. 2020; 11: 265-275.","DOI":"10.1055\/s-0040-1709715"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/1\/10.31083\/j.rcm.2021.01.267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:12:14Z","timestamp":1732727534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/1\/10.31083\/j.rcm.2021.01.267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"alternative-id":["1617068689998-482696708"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm.2021.01.267","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"article-number":"181"}}